1. Introduction {#sec1-ijms-19-01250}
===============

Everolimus (EVE), marketed as Certican, is a pharmacological agent widely used in the anti-rejection therapy of solid organ transplantation and in the treatment of certain tumors (e.g., in advanced renal cell carcinoma, subependymal giant cell astrocytoma associated with tuberous sclerosis, pancreatic neuroendocrine tumors, breast cancer) \[[@B1-ijms-19-01250]\]. Similar to Sirolimus and Tamsilorimus, it exerts its immunosuppressive activity by inhibiting mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein that controls cell cycle, protein synthesis, angiogenesis and autophagy \[[@B2-ijms-19-01250]\]. These important multi-factorial biological/cellular effects allow this drug to avoid/minimize the onset of acute rejection episodes and to slow down the progression of chronic allograft lesions \[[@B3-ijms-19-01250],[@B4-ijms-19-01250]\].

However, some authors have reported a high rate of discontinuation secondary to side effects after the introduction of this drug \[[@B5-ijms-19-01250],[@B6-ijms-19-01250],[@B7-ijms-19-01250]\]. Among them, pneumonitis or interstitial lung disease with a range of pulmonary histopathologic changes (including alveolar hemorrhage, pulmonary alveolar proteinosis, focal fibrosis, bronchiolitis obliterans organizing pneumonia) have been largely reported in clinical records and they have been associated with worsened patients' clinical outcomes and drug discontinuation \[[@B8-ijms-19-01250],[@B9-ijms-19-01250],[@B10-ijms-19-01250],[@B11-ijms-19-01250],[@B12-ijms-19-01250],[@B13-ijms-19-01250],[@B14-ijms-19-01250],[@B15-ijms-19-01250],[@B16-ijms-19-01250]\]. The incidence of this complications is 2--11%, frequently reported between 1 and 51 months after the beginning of mTOR inhibitor therapy \[[@B17-ijms-19-01250],[@B18-ijms-19-01250],[@B19-ijms-19-01250]\].

The pathogenic mechanism underlying lung toxicity is multi-factorial and epithelial to mesenchymal transition (EMT) of airway cells seems to have a pivotal role \[[@B20-ijms-19-01250],[@B21-ijms-19-01250],[@B22-ijms-19-01250],[@B23-ijms-19-01250]\]. Our group has recently demonstrated that high doses of EVE are associated with a reprogramming of gene expression in several epithelial cell lines (airway, renal epithelial proximal tubular and hepatic cells) with a consequent loss of their phenotype (junctions and apical-basal polarity) and the acquisition of mesenchymal traits increasing the motility and enabling the development of an invasive and pro-fibrotic phenotype \[[@B24-ijms-19-01250],[@B25-ijms-19-01250],[@B26-ijms-19-01250]\].

High dosage of EVE eliminating negative crosstalk from mTORC1/S6K, leads to activation of mTORC2 that enhances AKT phosphorylation at Ser473 and stimulates PI3K-AKT signaling that induces renal fibrosis \[[@B26-ijms-19-01250],[@B27-ijms-19-01250],[@B28-ijms-19-01250],[@B29-ijms-19-01250],[@B30-ijms-19-01250]\].

The pro-fibrotic attitude of EVE has also been confirmed in vivo in renal transplant patients through the estimation of an arbitrary pulmonary fibrosis index score in renal transplant patients chronically treated with this drug. In this patients' subset, high blood trough level of EVE was associated with a high rate of pulmonary signs of fibrosis \[[@B24-ijms-19-01250]\].

However, although the aforementioned studies and the large clinical evidences, the complete biological machinery involved in this condition has not been completely clarified.

Therefore, we employed, for the first time, a highthroughput approach combining a transcriptomic with a miRNome analysis to study the capability of EVE to induce pro-fibrotic changes in primary bronchial epithelial cells.

All together our results could represent a step forward in the comprehension of the mTOR-I associated biological machinery and in the identification of new targets for therapeutic interventions.

2. Results {#sec2-ijms-19-01250}
==========

2.1. High Dosage Everolimus (EVE) Induced Epithelial to Mesenchymal Transition (EMT) of BE63/3 (Primary Bronchial Epithelial Cells) {#sec2dot1-ijms-19-01250}
-----------------------------------------------------------------------------------------------------------------------------------

To confirm our previous results obtained in immortalized bronchial and pulmonary cell lines \[[@B24-ijms-19-01250]\], we decided to measure by Real Time-PCR the expression level of alpha smooth muscle actin (*α-SMA)*, vimentin (*VIM*), and fibronectin (*FN*) in BE63/3 treated for 24 h with 2 different dosages of EVE (5 and 100 nM) chosen according to literature evidences \[[@B31-ijms-19-01250],[@B32-ijms-19-01250],[@B33-ijms-19-01250],[@B34-ijms-19-01250]\] and previous experiments performed by our research group in different cell lines \[[@B24-ijms-19-01250],[@B25-ijms-19-01250],[@B26-ijms-19-01250]\].

Only high dose of EVE (100 nM), similarly to TGF-β (20 ng/mL), increased the mRNA level of the EMT-related markers ([Figure 1](#ijms-19-01250-f001){ref-type="fig"}A--C). Moreover E-cadherin resulted downregulated although it did not reach a statistically significant level ([Figure S1](#app1-ijms-19-01250){ref-type="app"}). Contrarily, 5 nM EVE was ineffective ([Figure 1](#ijms-19-01250-f001){ref-type="fig"}A--C).

Additionally, high dosage of EVE was also able to reduce the transepithelial resistance (TER) evaluated by a Millicell-ERS ohmmeter indicating dysfunctional tight junctions ([Figure 1](#ijms-19-01250-f001){ref-type="fig"}D).

2.2. Transcriptomic Analysis Revealed That High Dosage of EVE Up-Regulated Genes Involved in Collagen Synthesis and Metabolism {#sec2dot2-ijms-19-01250}
------------------------------------------------------------------------------------------------------------------------------

Gene expression profiling evaluated by transcriptomic analysis revealed that in vitro treatment of BE63/3 cells with 100 nM EVE for 24 h deregulated 147 probe sets (corresponding to 125 genes): 60/147 probe sets (47 genes) resulted up-regulated while 87/147 probe sets (corresponding to 78 genes) were down-regulated (≥1.5-fold change) in EVE-treated cells compared with control (CTR) ([Table 1](#ijms-19-01250-t001){ref-type="table"}). According to enrichment analysis, selected genes belonged to 44 pathways ([Table 2](#ijms-19-01250-t002){ref-type="table"}) and 5 of them were involved in collagen synthesis/metabolism and regulation of stress fiber assembly. Interestingly, connective tissue growth factor (*CTGF*) was a representative gene in all these pro-fibrotic pathways.

Instead, low dosage EVE (5 nM) was able to change the expression level of only 33 probe sets (24 genes): 25/33 probe sets (20 genes) were hyper-expressed and 4 probe sets (4 genes) down-regulated after treatment ([Table 3](#ijms-19-01250-t003){ref-type="table"}). None of the selected pathways was associated with the pro-fibrotic cellular machinery ([Table 4](#ijms-19-01250-t004){ref-type="table"}).

Principal component analysis (PCA) and volcano plot showed the degree of separation of untreated versus treated cells at both EVE dosages ([Figure 2](#ijms-19-01250-f002){ref-type="fig"}).

2.3. MiRNome Analysis Identified Specific MicroRNAs Deregulated by EVE {#sec2dot3-ijms-19-01250}
----------------------------------------------------------------------

To gain insights into the mechanism leading to EMT induced by EVE and to discover possible regulatory miRNAs of this effect, we performed a miRNome analysis by miRNA Complete Labeling and Hybridization kit. Statistical analysis identified three miRNAs up-regulated after high dosage (100 nM) ([Table 5](#ijms-19-01250-t005){ref-type="table"}) and four after treatment with EVE at low dosage (5 nM) ([Table 6](#ijms-19-01250-t006){ref-type="table"}). Among these, miR-8485 was the most up-regulated miRNA (more than 4-fold changes in both treatments).

By matching mRNA and miRNA expression data, we found that 31 genes were specific target of the three identified miRNAs ([Table 7](#ijms-19-01250-t007){ref-type="table"}).

2.4. Gene Expression and Protein Analysis for Matrix Metalloproteinase 12 (MMP12) and Connective Tissue Growth Factor (CTGF) Validated High-Throughput Results {#sec2dot4-ijms-19-01250}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

In order to validate microarray results, we measured by Real-Time PCR the level of mRNA expression of *MMP12* and *CTGF*. Both transcripts were up-regulated after treatment with 100 nM EVE. Contrarily 5 nM EVE had no effect ([Figure 3](#ijms-19-01250-f003){ref-type="fig"}A,B). In addition, western blot analysis of *CTGF* confirmed gene expression results at protein level ([Figure 3](#ijms-19-01250-f003){ref-type="fig"}C,D).

2.5. Validation of Transcriptomic Results in an Additional Primary Cell Line (BE121/3) {#sec2dot5-ijms-19-01250}
--------------------------------------------------------------------------------------

To confirm transcriptomic results, we decided to measure the expression level of 8 selected genes (involved in EMT) up-regulated after high dosage EVE in a new primary bronchial epithelial cell line. As showed in [Figure 4](#ijms-19-01250-f004){ref-type="fig"}, results were in line with those obtained in BE63/3 ([Figure 4](#ijms-19-01250-f004){ref-type="fig"}).

2.6. High Dosage EVE Up-Regulated CTGF and Collagen1 in Fibroblasts and Hepatic Stellate Cells {#sec2dot6-ijms-19-01250}
----------------------------------------------------------------------------------------------

To validate the pro-fibrotic effect of high dosage EVE we measured the expression level of collagen1 and CTGF in NIH/3T3 (mouse embryo fibroblast cell line) treated with EVE.

Interestingly, also in fibroblasts high dosage EVE up-regulated the protein levels of collagen1 and CTGF ([Figure 5](#ijms-19-01250-f005){ref-type="fig"}).

Also, in hepatic stellate cells high dosage EVE induced the up-regulation of CTGF and collagen1 ([Figure S2](#app1-ijms-19-01250){ref-type="app"}).

3. Discussion {#sec3-ijms-19-01250}
=============

Pulmonary fibrosis is a potential serious adverse effect following administration of mTOR-I in patients undergoing solid organ transplantation or receiving anti-cancer therapies. It is generally accepted that pulmonary disease is related to mTOR-I therapy, whether the following conditions are present: (1). The symptoms of pulmonary disease occur after initiation of mTOR-I therapy; (2). Infection, other pulmonary diseases or toxicity associated with other drugs are excluded; (3). mTOR-I minimization or discontinuation lead to resolution of the symptoms. In fact, the dose-dependent effect was proved by the observation of this disease particularly in patients receiving high doses of mTOR-I.

Pulmonary manifestations in these patients are numerous and include several clinical/histological phenotypes (e.g., focal pulmonary fibrosis, bronchiolitis obliterans with organizing pneumonia) \[[@B8-ijms-19-01250],[@B9-ijms-19-01250],[@B35-ijms-19-01250],[@B36-ijms-19-01250]\].

This multi-factorial and heterogeneous clinical condition is often responsible for drug discontinuation and it requires long and expensive clinical evaluations and treatments (e.g., antibiotics, corticosteroids, immunosuppressive drugs) \[[@B14-ijms-19-01250]\] with the involvement of a multidisciplinary team of experts (e.g., pulmonologists, infectivologists, nephrologists).

The etiopathogenic mechanism of pulmonary toxicity associated with mTOR-I therapy is not known and several in vivo and in vitro studies have tried to define the underlying mechanisms. It has been proposed a T cell-mediated autoimmune response induced when pulmonary cryptic antigens are exposed, leading to lymphocytic alveolitis and interstitial pneumonitis \[[@B15-ijms-19-01250]\]. Other possible pathogenic mechanisms could be a delayed-type hypersensitivity reaction \[[@B9-ijms-19-01250]\] or pulmonary inflammation as a direct effect of mTOR-I to stimulate cells of the innate immune system to produce proinflammatory cytokines \[[@B37-ijms-19-01250],[@B38-ijms-19-01250]\].

Additionally, Ussavarungsi et al. have reported that sirolimus may induce granulomatous interstitial inflammation and proposed a mechanism of T-cell mediated hypersensitivity reaction triggered by circulating antigens or immune complexes in the lungs \[[@B39-ijms-19-01250]\].

Moreover, several authors have emphasized the pathogenetic role of the EMT of bronchial epithelial cells in these important Everolimus (EVE)-related adverse events \[[@B20-ijms-19-01250],[@B21-ijms-19-01250],[@B22-ijms-19-01250],[@B23-ijms-19-01250]\].

To obtain more insights, we decided to employ, for the first time, innovative high throughput technologies, to identify new elements involved in the biological/cellular reprogramming induced by high dose of mTOR-I and leading to fibrosis.

In vitro experiments using classical bio-molecular strategies, confirmed, in primary bronchial epithelial cell lines, our previous results demonstrating the ability of high dosages EVE to induce EMT. In particular, 100 nM EVE caused the up-regulation of EMT-related genes (*α-SMA, VIM, FN*) and reduced the trans-epithelial resistance to the same levels induced by TGF-β. Then, high doses of this drug significantly changed the expression level of 125 genes (47 up- and 78 down-regulated).

Several of the selected genes were target of miR-8485, the top significant and up-regulated microRNA (miRNA) by EVE 100 nM. Other 2 miRNAs were identified after the same treatment: miR-937-5p and miR-5194. Except for miR-8485, at our knowledge, none of them has been previously associated with fibrosis or supposed to be regulatory of genes implicated in this process. It's unquestionable that further studies are warranted to confirm the involvement of these miRNAs in EVE induced EMT since all identified miRNAs were up-regulated demonstrating their possible role as enhancer of fibrotic machinery. This could be in line with recent findings suggesting that miRNA-mediated down-regulation is not a one-way process and some miRNAs could up-regulate gene expression in specific cell types and conditions with distinct transcripts and proteins \[[@B40-ijms-19-01250],[@B41-ijms-19-01250]\]. It is noteworthy that these miRNAs are up-regulated also after treatment with 5 nM EVE. Many reasons could be responsible of this effect. In particular, the expression of these miRNAs could be regulated by several factors and networks (some of them also unrelated to mTOR-I treatment). Additional studies are needed to clarify the role of miRNA in EVE-mediated pro-fibrotic effect.

Moreover, analyzing the results of the transcriptomic analysis and the hypothetic targets of miR-8485, we found that connective tissue growth factor (*CTGF*), a protein secreted into the extracellular environment where it interacts with distinct cell surface receptors, growth factors and extra-cellular matrix \[[@B42-ijms-19-01250],[@B43-ijms-19-01250]\] was one of the top scored genes. Gene expression by RT-PCR and protein analysis by western blotting confirmed the result obtained by microarray.

It is well known that CTGF modulates the activities of TGF-β or vascular endothelial growth factor (*VEGF*), with consequent pro-fibrotic and angiogenetic effects \[[@B44-ijms-19-01250],[@B45-ijms-19-01250],[@B46-ijms-19-01250],[@B47-ijms-19-01250]\]. However, the overexpression of CTGF in fibroblast of mice caused tissue fibrosis in vivo \[[@B48-ijms-19-01250]\] without involving the canonical TGF-β pathway. This is in line with several reports that demonstrated a mTOR-I dose-related induction of CTGF at gene and protein levels in vitro and in vivo \[[@B49-ijms-19-01250],[@B50-ijms-19-01250],[@B51-ijms-19-01250],[@B52-ijms-19-01250]\].

Moreover, Xu et al. have demonstrated that rapamycin, an analogue of EVE, exerted a profibrotic effect in lung epithelial cells as well as in lung fibroblasts via up-regulation of CTGF expression and PI3K/AKT pathway \[[@B50-ijms-19-01250],[@B51-ijms-19-01250]\]. Similarly, Mikaelian et al. using a combination of RNAi and pharmacological approaches showed that inhibition of mTOR triggers EMT in mammalian epithelial cells by a mechanism TGF-β independent \[[@B53-ijms-19-01250]\]. In the transplant context it has been described a synergistic fibrotic effect of sirolimus with cyclosporine in kidney also mediated by the up-regulation of CTGF \[[@B54-ijms-19-01250],[@B55-ijms-19-01250]\].

Another interested gene up-regulated by EVE, selected by microarray and validated by RT-PCR, was metalloproteinase 12 (*MMP12*), a member of the zinc-dependent endopeptidases family able to proteolyze all components of the extracellular matrix \[[@B56-ijms-19-01250],[@B57-ijms-19-01250]\] by degrading collagen, other extracellular filaments, cytokines, growth factors and their receptors. *MMP12* has a pivotal role in TGF-β mediated pulmonary fibrosis \[[@B58-ijms-19-01250],[@B59-ijms-19-01250]\].

Interestingly, other identified genes by transcriptomic analysis and target of miR-8485 ([Table 7](#ijms-19-01250-t007){ref-type="table"}) were Kallmann syndrome-1 gene (*KAL1*, fold change: 1.705), Limb-bud and heart (*LBH*, fold change: 1.808) and insulin receptor substrates 2 (*IRS2*, fold change: 1.646) that resulted up-regulated after 100 nM EVE treatment and Protocadherin 7 (*PCDH7*, fold change: −1.625) down-regulated by similar treatment. All of them have been described in literature as directly or indirectly involved in the EMT.

*KAL1*, codes for anosmin-1, a cell adhesion protein in extracellular matrix induced by TGF-β \[[@B60-ijms-19-01250],[@B61-ijms-19-01250]\]. *IRS2* expression appears to repress the expression of E-cadherin \[[@B62-ijms-19-01250]\], marker of epithelial cells deregulated during EMT.

*LBH* is a transcription cofactor with both transcriptional activator and corepressor functions. *LBH* is a direct Wnt/β-catenin target gene and is induced by TGF-β \[[@B63-ijms-19-01250],[@B64-ijms-19-01250]\]. Wnt/β-catenin signaling activation occurs in cells during EMT \[[@B65-ijms-19-01250]\] and treated with mTOR-I.

Protocadherin 7 is an integral membrane protein having a role in cell--cell recognition and adhesion. Down-regulation of *PCDH7* gene was correlated with E-cadherin inhibition \[[@B66-ijms-19-01250]\].

All these findings, although speculatively interesting, need to be validated in vivo. Our study is an hypothesis generating study that should be considered a starting point for bio-molecular study involving transplanted patients or animal models.

Nevertheless, after 21 days in culture, most of the cells were not ciliated and we cannot exclude that differentiation state may have affected the response to EVE ([Figure S3](#app1-ijms-19-01250){ref-type="app"}).

However, our results suggested that high concentrations of EVE, through the activation of a multi-factorial biological/cellular machinery, may lead to pulmonary fibrosis and underlined potential pathogenetic, diagnostic biomarkers and targets for future pharmacological interventions to introduce in the "day by day" clinical practice. Finally, at a clinical point of view, we confirm that, whenever possible, the dose of EVE should be the minimized in patients with early signs of lung toxicity.

4. Materials and Methods {#sec4-ijms-19-01250}
========================

4.1. Cell Culture Treatment {#sec4dot1-ijms-19-01250}
---------------------------

Primary wild-type bronchial epithelial cells (BE63/3 and BE121/3) were obtained from "Servizio Colture Primarie" of the Italian Cystic Fibrosis Research Foundation (ICFRF) and cultured following the supplier instructions \[[@B67-ijms-19-01250]\]. The protocols to isolate, culture, store, and study bronchial epithelial cells from patients undergoing lung transplant was approved by the Ethical Committee of Gaslini Institute (ethical approval number IGG:192 date of approval: 9/24/2010) under the supervision of the Italian Ministry of Health. Cells were grown on rat tail collagen-coated tissue culture plates in serum-free LHC9/RPMI 1640 medium at 37 °C and 5% CO~2~.

After 4--5 passages, cells were seeded on Transwell porous inserts. After 24 h from seeding, the medium was switched to DMEM/F12 supplemented with 2% Ultroser G, 2 mM [l]{.smallcaps}-glutammine, 100 U/mL penicillin, 100 μg/mL streptomycin.

Exchange of culture medium is repeated every day on both sides of permeable supports up to 5 days. Then the apical culture medium was removed, and the medium was added only in the basolateral side (air-liquid interface) favoring a differentiation of the epithelium ([Figure S3](#app1-ijms-19-01250){ref-type="app"}). After 11 days the epithelium was treated with EVE (5 nM and 100 nM) and TGF-β (20 ng/mL), an EMT inducer, for 24 h. "The timing of cell culture for gene expression and western blot experiments (17 days) was based on clear instructions supplied by the "Servizio Colture Primarie" of the ICFRF in order to reach the differentiation of epithelium". Although the in vitro model cannot completely represent the in vivo pharmacokinetic/effect of this drug, we can postulate that 5 nM EVE corresponds to a trough level of approximately 5 ng/mL (drug level frequently reached in the immunosuppressive maintenance therapy of solid organ transplantation), while 100 nM may correspond to very high dosages (trough level more than 50 ng/mL) that patients could reach in anticancer therapy.

NIH/3T3 fibroblasts, purchased from American Type Culture Collection (Manassas, VA, USA) were maintained at 37 °C in DMEM supplemented with 10% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM [l]{.smallcaps}-glutamine. Cells were treated with or without 5 and 100 nM Everolimus for 24 h.

4.2. RNA Extraction and Gene Expression Profiling {#sec4dot2-ijms-19-01250}
-------------------------------------------------

Trizol reagent (Invitrogen) was used to extract total RNA and then, yield and purity were checked using a Nanodrop spectrophotometer.

Gene expression data were produced using the HumanHT-12 v3 Expression BeadChip (Release 38, Illumina, San Diego, CA, USA). Five hundred ng total RNA from BE63/3 was used to synthesize biotin-labeled cRNA using the Illumina^®^TotalPrep™ RNA amplification kit (Applied Biosystems, Foster City, CA, USA). Quality of labelled cRNA was assessed by NanoDrop^®^ ND-100 spectrophotometer and the Agilent 2100 Bioanalyzer. Then, 750 ng biotinylated cRNA was used for hybridization to illumina microarrays that were then scanned with the HiScanSQ.

4.3. Pathway Analysis {#sec4dot3-ijms-19-01250}
---------------------

The Ingenuity Pathway Analysis software (IPA, Ingenuity System, Redwood City, CA, USA) was used to assess biological relationships among differentially regulated genes. The reference gene selection was performed by own software written in Java program language. The canonical pathways generated by IPA are the most significant for the uploaded data set. Fischer's exact test with false discovery rate (FDR) option was used to calculate the significance of the canonical pathway.

4.4. MicroRNA Expression Profiling {#sec4dot4-ijms-19-01250}
----------------------------------

Fluorescently-labeled miRNAs were generated using the miRNA Complete Labeling and Hybridization kit (Agilent Technologies, Santa Clara, CA, USA), with a sample input of 100 ng of total RNA from BE63/3 and hybridized for 20 h at 55 °C on the Agilent 8 × 60 K Human miRNA Microarray slide (Agilent Technologies), based on miRBase database (Release 21.0). Following hybridization, the slides were washed and scanned using the High-Resolution Microarray C Scanner (Agilent Technologies). The image files were processed using the Agilent Feature Extraction software (v10.7.3): the microarray grid was correctly placed; inlier pixels were identified, and outlier pixels were rejected.

4.5. Real-Time PCR {#sec4dot5-ijms-19-01250}
------------------

Five hundred ng total RNA from each sample was reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR amplification reactions were performed in duplicate via SYBR Green chemistry on CFX-connect (Bio-Rad, Hercules, CA, USA) and SsoAdvanced™ Universal SYBR^®^ Green Supermix (Bio-Rad). Primers for α-SMA, VIM, FN, MMP12, CTGF, CDH6, COL12A1, FAP, KAL1, LBH, PIM1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from Qiagen (QuantiTect Primer Assay, Hilden, Germany).

The comparative *C*~t~ method (ΔΔ*C*~t~) was used to quantify gene expression and the relative quantification was calculated as 2^−ΔΔ*C*t^. Melting curve analysis was employed to exclude non-specific amplification products.

4.6. Western Blot {#sec4dot6-ijms-19-01250}
-----------------

Equal amounts of proteins were resolved in 10% SDS-PAGE and electrotransferred to nitrocellulose membranes. Non-specific binding was blocked for 1 h at room temperature with non-fat milk (5%) in TBST buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20). Membranes were exposed to primary antibodies directed against GAPDH (Santa Cruz sc-25778), CTGF (NovusBio, Littleton, CO, USA) and collagen1 (ORIGENE TA309096) (overnight at 4 °C) and incubated with a secondary peroxidase-conjugated antibody for 1 h at room temperature. The signal was detected with SuperSignals West Pico Chemiluminescent substrate solution (Pierce) according to the manufacturer's instructions.

4.7. Transepithelial Resistance (TER) {#sec4dot7-ijms-19-01250}
-------------------------------------

Millicell-ERS ohmmeter with electrodes (Millipore) was used to measure TER (alternating current applied between the electrodes: ±20 μA and frequency: 12.5 Hz). The resistance of the monolayer multiplied by the effective surface area was used to obtain the electrical resistance of the monolayer (Ω cm^2^). Once stable resistances were obtained, different culture media (control, EVE 5 nM, EVE 100 nM, TGF-β 20 ng/mL) were tested. After the addition of test solutions, measurements were taken at 24 h.

4.8. Statistical Analysis {#sec4dot8-ijms-19-01250}
-------------------------

For transcriptomics statistical analyses were carried out by Genespring GX 11.0 software (Agilent Technologies). Gene probe sets were filtered based on the FDR method of Benjamini--Hochberg and fold-change. Only genes that were significantly (adjusted-*p* value \< 0.05 and fold-change \> 1.5) modulated were considered for further analysis.

In the miRNome analysis, after normalization (Quantile method), unpaired *t*-test (*p*-value cut-off: 0.05 and fold-change cut-off: 2.0, after Benjamini--Hochberg multiple testing correction) was employed to identify most differentially expressed probes.

For the statistical analysis of RT-PCR and western-blot, differences between control and treated cell were compared using Student's *t*-test. A *p*-value \< 0.05 was set as statistically significant.

This study was funded by grants from the Italian Cystic Fibrosis (CF) Research Foundation (FFC\#28/2014, Delegazione FFC di Torino, Lodi/Latina, Italy) and from the Fondazione Cariverona 2015. This study was performed in the LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University of Verona, Verona, Italy.

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/19/4/1250/s1>.
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![Gene expression of epithelial to mesenchymal transition (EMT) related markers. Relative (**A**) alpha smooth muscle actin (*α-SMA*), (**B**) fibronectin (*FN*) and (**C**) vimentin (*VIM*) expression evaluated by Real-time PCR in BE 63/3 cells treated or untreated with Everolimus (EVE) (5 and 100 nM) or TGF-β (20 ng/mL); expression values were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Mean ± S.D. (error bars) of three separate experiments performed in triplicate. \* *p* \< 0.05, \*\* *p* \< 0.01 vs. control (CTR). (**D**) Histogram represents transepithelial resistance as percentage change with respect to control cells. \* *p* \< 0.05 vs. CTR.](ijms-19-01250-g001){#ijms-19-01250-f001}

![Principal Component Analysis (PCA) and Volcano Plot discriminating BE63/3 CTR from EVE treated cells. PCA plots were built using the expression level of all differentially expressed genes obtained from mRNA expression profiling after treatment with (**A**) 5 nM and (**C**) 100 nM EVE. Volcano Plot based on fold change (Log2) and p value (−Log10) of all genes identified in BE63/3 after treatment with (**B**) 5 nM and (**D**) 100 nM EVE. In both graphs red circles indicate the genes that showed statistically significant change.](ijms-19-01250-g002){#ijms-19-01250-f002}

![Gene expression of *MMP12* and connective tissue growth factor (*CTGF*). mRNA level of (**A**) *MMP12* and (**B**) *CTGF* evaluated by real-time PCR in BE63/3 cells treated or not with EVE (5 and 100 nM). Data were normalized to GAPDH expression. Mean ± SD (error bars) of two separate experiments performed in triplicate. \*\* *p* \< 0.001, \* *p* \< 0.05 vs. CTR. (**C**) Representative western blotting experiments for *CTGF*. (**D**) Histogram represents the mean ± SD of *CTGF* protein level. *GAPDH* was included as loading control. \*\* *p* \< 0.001 vs. CTR.](ijms-19-01250-g003){#ijms-19-01250-f003}

![Gene expression in BE121/3. mRNA level of (**A**) *CDH6*, (**B**) *COL12A1*, (**C**) *CTGF*, (**D**) *FAP*, (**E**) *KAL1*, (**F**) *LBH*, (**G**) *MMP12*, (**H**) *PIM1* evaluated by real-time PCR in BE121/3 cells treated or not with EVE (5 and 100 nM). Data were normalized to *GAPDH* expression. Mean ± SD (error bars) of two separate experiments performed in triplicate. \*\* *p* \< 0.001, \* *p* \< 0.05 vs. CTR.](ijms-19-01250-g004){#ijms-19-01250-f004}

![Protein levels of collagen1 and CTGF in NIH/3T3 cells. (**A**) Representative western blotting experiments for collagen1 and CTGF. Histograms represent the mean ± SD of (**B**) collagen1 and (**C**) CTGF protein levels. GAPDH was included as loading control. \*\* *p* \< 0.001, \* *p* \< 0.05 vs. CTR.](ijms-19-01250-g005){#ijms-19-01250-f005}
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###### 

List of the differentially expressed probe sets after treatment with 100 nM EVE.

  Probe ID   Fold Change   Regulation   Symbol      Entrez Gene ID   Definition
  ---------- ------------- ------------ ----------- ---------------- -------------------------------------------------------------------------------------------------------------------------------
  4760626    2.275         Up           MMP12       4321             matrix metallopeptidase 12 (macrophage elastase), mRNA.
  4780209    2.218         Up           MMP12       4321             matrix metallopeptidase 12 (macrophage elastase) mRNA.
  670041     1.925         Up           AKAP12      9590             A kinase (PRKA) anchor protein (gravin) 12, transcript variant 2, mRNA.
  6770746    1.903         Up           LOC728715   728715           similar to hCG38149 (LOC728715), mRNA.
  4640086    1.814         Up           FOXQ1       94234            forkhead box Q1, mRNA.
  2810246    1.808         Up           LBH         81606            limb bud and heart development homolog (mouse) (LBH), mRNA.
  6330270    1.804         Up           GPC4        2239             glypican 4, mRNA.
  6620201    1.789         Up           KLHL24      54800            kelch-like 24 (Drosophila), mRNA.
  5690687    1.783         Up           CTGF        1490             connective tissue growth factor, mRNA.
  5420577    1.775         Up           CLCA4       22802            chloride channel, calcium activated, family member 4, mRNA.
  2640292    1.769         Up           CTGF        1490             connective tissue growth factor, mRNA.
  1070477    1.753         Up           ALDH1A1     216              aldehyde dehydrogenase 1 family, member A1, mRNA.
  3130301    1.729         Up           PIM1        5292             pim-1 oncogene, mRNA.
  6620008    1.705         up           KAL1        3730             Kallmann syndrome 1 sequence, mRNA.
  4040576    1.704         up           IL6         3569             interleukin 6 (interferon, beta 2), mRNA.
  1820315    1.677         up           C4orf26     152816           chromosome 4 open reading frame 26 (C4orf26), mRNA.
  1990142    1.671         up           C20orf114   92747            chromosome 20 open reading frame 114 (C20orf114), mRNA.
  1940647    1.668         up           HBP1        26959            HMG-box transcription factor 1, mRNA.
  2640324    1.665         up           SLC46A3     283537           solute carrier family 46, member 3, mRNA.
  3800241    1.651         up           CDH6        1004             cadherin 6, type 2, K-cadherin (fetal kidney), mRNA.
  6110736    1.646         up           IRS2        8660             insulin receptor substrate 2, mRNA.
  4610056    1.641         up           FLRT2       23768            fibronectin leucine rich transmembrane protein 2, mRNA.
  6420687    1.638         up           PLUNC       51297            palate, lung and nasal epithelium carcinoma associated, transcript variant 2, mRNA.
  6420465    1.625         up           GABARAPL1   23710            GABA(A) receptor-associated protein like 1, mRNA.
  4780128    1.625         up           ATF3        467              activating transcription factor 3, transcript variant 4, mRNA.
  160242     1.622         up           C13orf15    28984            chromosome 13 open reading frame 15 (C13orf15), mRNA.
  2650709    1.620         up           CDH11       1009             cadherin 11, type 2, OB-cadherin (osteoblast), mRNA.
  2230767    1.615         up           LOC387825   387825           misc_RNA (LOC387825), miscRNA.
  6860228    1.610         up           C5orf41     153222           chromosome 5 open reading frame 41 (C5orf41), mRNA.
  6510754    1.609         up           ALDH1A1     216              aldehyde dehydrogenase 1 family, member A1, mRNA.
  1980255    1.605         up           RNF39       80352            ring finger protein 39, transcript variant 2, mRNA.
  6840491    1.604         up           C5orf41     153222           chromosome 5 open reading frame 41 (C5orf41), mRNA.
  4280228    1.595         up           IVNS1ABP    10625            influenza virus NS1A binding protein, mRNA.
  5080021    1.593         up           BIRC3       330              baculoviral IAP repeat-containing 3, transcript variant 1, mRNA.
  6400131    1.589         up           CYP24A1     1591             cytochrome P450, family 24, subfamily A, polypeptide 1, nuclear gene encoding mitochondrial protein, mRNA.
  7160239    1.580         up           FOSB        2354             FBJ murine osteosarcoma viral oncogene homolog B, mRNA.
  380689     1.578         up           TSC22D1     8848             TSC22 domain family, member 1, transcript variant 1, mRNA.
  3060095    1.574         up           COL12A1     1303             collagen, type XII, alpha 1, transcript variant short, mRNA.
  1410209    1.571         up           SGK1        6446             serum/glucocorticoid regulated kinase 1, transcript variant 1, mRNA.
  2190553    1.556         up           FZD6        8323             frizzled homolog 6 (Drosophila), mRNA.
  4570075    1.544         up           KIAA1641    57730            KIAA1641, transcript variant 7, mRNA.
  5090626    1.540         up           FAP         2191             fibroblast activation protein, alpha, mRNA.
  6620538    1.540         up           UBL3        5412             ubiquitin-like 3, mRNA.
  5960398    1.537         up           NT5E        4907             5′-nucleotidase, ecto (CD73), mRNA.
  5570731    1.533         up           C8orf4      56892            chromosome 8 open reading frame 4 (C8orf4), mRNA.
  830639     1.531         up           LOC653778   653778           similar to solute carrier family 25, member 37 (LOC653778), mRNA.
  3290187    1.529         up           PCMTD1      115294           protein-[l]{.smallcaps}-isoaspartate ([d]{.smallcaps}-aspartate) O-methyltransferase domain containing 1 (PCMTD1), mRNA.
  3440670    1.517         up           LOC402251   402251           similar to eukaryotic translation elongation factor 1 alpha 2 (LOC402251), mRNA.
  630315     1.514         up           DHRS9       10170            dehydrogenase/reductase (SDR family) member 9, transcript variant 1, mRNA.
  1410161    1.513         up           KLHL5       51088            kelch-like 5 (Drosophila), transcript variant 3, mRNA.
  4150575    1.513         up           LETMD1      25875            LETM1 domain containing 1, transcript variant 2, mRNA.
  7210497    1.513         up           NUAK1       9891             NUAK family, SNF1-like kinase, 1, mRNA.
  1240440    1.511         up           TXNIP       10628            thioredoxin interacting protein, mRNA.
  4760747    1.509         up           TPST1       8460             tyrosylprotein sulfotransferase 1, mRNA.
  2360220    1.508         up           MATR3       9782             matrin 3, transcript variant 1, mRNA.
  3800431    1.508         up           RCOR3       55758            REST corepressor 3, mRNA.
  4390450    1.504         up           SGK         6446             serum/glucocorticoid regulated kinase, mRNA.
  2450465    1.503         up           CYBRD1      79901            cytochrome b reductase 1, mRNA.
  6110053    1.501         up           ZNF32       7580             zinc finger protein 32, transcript variant 2, mRNA.
  4570398    1.501         up           F2R         2149             coagulation factor II (thrombin) receptor, mRNA.
  3800050    −1.503        down         ADCY3       109              adenylate cyclase 3, mRNA.
  5900008    −1.504        down         KLK11       11012            kallikrein-related peptidase 11, transcript variant 2, mRNA.
  5080605    −1.504        down         SNRPA1      6627             small nuclear ribonucleoprotein polypeptide A′, mRNA.
  4560541    −1.521        down         MLKL        197259           mixed lineage kinase domain-like, mRNA.
  520682     −1.523        down         CPA4        51200            carboxypeptidase A4, mRNA.
  4010296    −1.527        down         RNASE1      6035             ribonuclease, RNase A family, 1 (pancreatic), transcript variant 1, mRNA.
  6350161    −1.530        down         LCP1        3936             lymphocyte cytosolic protein 1 ([l]{.smallcaps}-plastin), mRNA.
  4730605    −1.532        down         AURKA       6790             aurora kinase A, transcript variant 5, mRNA.
  6840075    −1.532        down         NP          4860             nucleoside phosphorylase, mRNA.
  6770187    −1.533        down         SPRR2A      6700             small proline-rich protein 2A, mRNA.
  870131     −1.533        down         HSPA5       3309             heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa), mRNA.
  1570193    −1.535        down         ARHGDIB     397              Rho GDP dissociation inhibitor (GDI) beta, mRNA.
  2450167    −1.537        down         RPL29       6159             ribosomal protein L29, mRNA.
  7510709    −1.540        down         CEP55       55165            centrosomal protein 55 kDa, mRNA.
  2350465    −1.544        down         RPL29       6159             ribosomal protein L29, mRNA.
  160097     −1.546        down         MELK        9833             maternal embryonic leucine zipper kinase, mRNA.
  3930703    −1.547        down         WDR4        10785            WD repeat domain 4, transcript variant 2, mRNA.
  1170066    −1.554        down         SULT2B1     6820             sulfotransferase family, cytosolic, 2B, member 1, transcript variant 1, mRNA.
  2070520    −1.556        down         CDCA7       83879            cell division cycle associated 7, transcript variant 1, mRNA.
  6550048    −1.559        down         DHCR7       1717             7-dehydrocholesterol reductase, mRNA.
  5310634    −1.566        down         FASN        2194             fatty acid synthase, mRNA.
  6560494    −1.566        down         ARTN        9048             artemin, transcript variant 2, mRNA.
  5860348    −1.568        down         SC4MOL      6307             sterol-C4-methyl oxidase-like, transcript variant 2, mRNA.
  5270112    −1.570        down         HMGCS1      3157             3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble), transcript variant 2, mRNA.
  5690274    −1.571        down         MCM6        4175             minichromosome maintenance complex component 6, mRNA.
  940487     −1.573        down         FUT3        2525             fucosyltransferase 3 (galactoside 3(4)-[l]{.smallcaps}-fucosyltransferase, Lewis blood group), transcript variant 4, mRNA.
  5810154    −1.580        down         ALOX15B     247              arachidonate 15-lipoxygenase, type B, transcript variant b, mRNA.
  870546     −1.581        down         MAD2L1      4085             MAD2 mitotic arrest deficient-like 1 (yeast), mRNA.
  6020139    −1.588        down         KLK7        5650             kallikrein-related peptidase 7, transcript variant 1, mRNA.
  4250156    −1.589        down         EBP         10682            emopamil binding protein (sterol isomerase), mRNA.
  10341      −1.599        down         SHMT2       6472             serine hydroxymethyltransferase 2 (mitochondrial), nuclear gene encoding mitochondrial protein, mRNA.
  5360678    −1.602        down         DHCR7       1717             7-dehydrocholesterol reductase, transcript variant 1, mRNA.
  6580059    −1.610        down         UCP2        7351             uncoupling protein 2 (mitochondrial, proton carrier), nuclear gene encoding mitochondrial protein, mRNA.
  5090278    −1.610        down         GPX2        2877             glutathione peroxidase 2 (gastrointestinal), mRNA.
  3940673    −1.617        down         LOC728285   728285           similar to keratin associated protein 2-4 (LOC728285), mRNA.
  2650564    −1.623        down         RARRES3     5920             retinoic acid receptor responder (tazarotene induced) 3, mRNA.
  360367     −1.625        down         PCDH7       5099             protocadherin 7, transcript variant a, mRNA.
  7560364    −1.635        down         LOC729779   729779           misc_RNA (LOC729779), miscRNA.
  780528     −1.635        down         CKS2        1164             CDC28 protein kinase regulatory subunit 2, mRNA.
  5960224    −1.636        down         PTTG3P      26255            pituitary tumor-transforming 3 (pseudogene), non-coding RNA.
  4730196    −1.653        down         TK1         7083             thymidine kinase 1, soluble, mRNA.
  1510296    −1.656        down         ASNS        440              asparagine synthetase, transcript variant 1, mRNA.
  1190142    −1.657        down         EMILIN2     84034            elastin microfibril interfacer 2, mRNA.
  1170170    −1.662        down         STC2        8614             stanniocalcin 2, mRNA.
  2140128    −1.670        down         SCD         6319             stearoyl-CoA desaturase (delta-9-desaturase), mRNA.
  5360070    −1.674        down         CCNB2       9133             cyclin B2, mRNA.
  3990619    −1.675        down         TOP2A       7153             topoisomerase (DNA) II alpha 170 kDa, mRNA.
  3780047    −1.679        down         GBP6        163351           guanylate binding protein family, member 6, mRNA.
  2000148    −1.683        down         IFIT1       3434             interferon-induced protein with tetratricopeptide repeats 1, transcript variant 2, mRNA.
  2070494    −1.700        down         PRC1        9055             protein regulator of cytokinesis 1, transcript variant 2, mRNA.
  10414      −1.704        down         PTTG1       9232             pituitary tumor-transforming 1, mRNA.
  2940110    −1.720        down         UHRF1       29128            ubiquitin-like with PHD and ring finger domains 1, transcript variant 1, mRNA.
  1510291    −1.733        down         PTTG1       9232             pituitary tumor-transforming 1, mRNA.
  1780446    −1.739        down         PCK2        5106             phosphoenolpyruvate carboxykinase 2 (mitochondrial), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA.
  1660521    −1.745        down         SPRR2D      6703             small proline-rich protein 2D, mRNA.
  730689     −1.763        down         LOC652595   652595           similar to U2 small nuclear ribonucleoprotein A (U2 snRNP-A) (LOC652595), mRNA.
  5090754    −1.766        down         KIAA0101    9768             KIAA0101, transcript variant 1, mRNA.
  5080139    −1.789        down         PRSS3       5646             protease, serine, 3 (mesotrypsin), mRNA.
  3800452    −1.805        down         EMP3        2014             epithelial membrane protein 3, mRNA.
  1230047    −1.810        down         CBS         875              cystathionine-beta-synthase, mRNA.
  6370615    −1.858        down         TGM1        7051             transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase), mRNA.
  5310471    −1.894        down         UBE2C       11065            ubiquitin-conjugating enzyme E2C, transcript variant 6, mRNA.
  7380719    −1.897        down         IGFBP6      3489             insulin-like growth factor binding protein 6, mRNA.
  940327     −1.907        down         KLK13       26085            kallikrein-related peptidase 13, mRNA.
  520195     −1.914        down         TMEM79      84283            transmembrane protein 79, mRNA.
  4040398    −1.954        down         MAL         4118             mal, T-cell differentiation protein, transcript variant d, mRNA.
  1990630    −1.979        down         TRIB3       57761            tribbles homolog 3 (Drosophila), mRNA.
  430446     −1.996        down         KRT81       3887             keratin 81, mRNA.
  4260368    −2.022        down         UBE2C       11065            ubiquitin-conjugating enzyme E2C, transcript variant 3, mRNA.
  290767     −2.038        down         KRTDAP      388533           keratinocyte differentiation-associated protein, mRNA.
  6520139    −2.046        down         FGFR3       2261             fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism), transcript variant 2, mRNA.
  620102     −2.046        down         MALL        7851             mal, T-cell differentiation protein-like, mRNA.
  5870653    −2.050        down         LOC651397   651397           misc_RNA (LOC651397), miscRNA.
  4050398    −2.071        down         KLK12       43849            kallikrein-related peptidase 12, transcript variant 1, mRNA.
  7330753    −2.102        down         ACAT2       39               acetyl-Coenzyme A acetyltransferase 2, mRNA.
  4900458    −2.147        down         KRT14       3861             keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner), mRNA.
  540546     −2.283        down         KRT4        3851             keratin 4, mRNA.
  1500010    −2.322        down         CDC20       991              cell division cycle 20 homolog (*S. cerevisiae*), mRNA.
  6550356    −2.430        down         SPRR2C      6702             small proline-rich protein 2C (pseudogene), non-coding RNA.
  4850674    −2.452        down         PSAT1       29968            phosphoserine aminotransferase 1, transcript variant 2, mRNA.
  5890400    −2.577        down         SPRR2E      6704             small proline-rich protein 2E, mRNA.
  240086     −2.608        down         PHGDH       26227            phosphoglycerate dehydrogenase, mRNA.
  7650441    −2.696        down         FGFBP1      9982             fibroblast growth factor binding protein 1, mRNA.
  5810546    −2.894        down         SPRR2E      6704             small proline-rich protein 2E, mRNA.
  7330184    −2.933        down         SPRR1A      6698             small proline-rich protein 1A, mRNA.
  2230035    −2.936        down         KRT13       3860             keratin 13, transcript variant 2, mRNA.
  4610131    −3.284        down         SPRR3       6707             small proline-rich protein 3, transcript variant 1, mRNA.

In red up-regulated and in green down-regulated genes in BE63/3 cells treated with 100 nM EVE compared to CTR.
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###### 

List of pathways differentially regulated after 100 nM EVE.

  Pathways                                                                                         Adj. *p* Value   Associated Genes
  ------------------------------------------------------------------------------------------------ ---------------- ---------------------------------------------------------------------------------------------------------------
  Epidermis development                                                                            1.24 × 10^−6^    *ALOX15B, CTGF, FOXQ1, FZD6, KLK7, KRT14, RNASE1, SPRR1A, SPRR2A, SPRR2D, SPRR2E, SPRR3, TGM1, TMEM79, TXNIP*
  Keratinization                                                                                   5.22 × 10^−6^    *SPRR1A, SPRR2A, SPRR2D, SPRR2E, SPRR3, TGM1, TMEM79*
  Negative regulation of cell division                                                             2.58 × 10^−5^    *CDC20, FGFR3, MAD2L1, PTTG1, PTTG3P, RGCC, TXNIP, UBE2C*
  Negative regulation of mitotic nuclear division                                                  2.81 × 10^−5^    *CDC20, FGFR3, MAD2L1, PTTG1, PTTG3P, RGCC, UBE2C*
  Keratinocyte differentiation                                                                     3.05 × 10^−5^    *ALOX15B, SPRR1A, SPRR2A, SPRR2D, SPRR2E, SPRR3, TGM1, TMEM79, TXNIP*
  L-serine metabolic process                                                                       3.54 × 10^−5^    *CBS, PHGDH, PSAT1, SHMT2*
  Epidermal cell differentiation                                                                   9.21 × 10^−5^    *ALOX15B, RNASE1, SPRR1A, SPRR2A, SPRR2D, SPRR2E, SPRR3, TGM1, TMEM79, TXNIP*
  L-serine biosynthetic process                                                                    9.75 × 10^−5^    *PHGDH, PSAT1, SHMT2*
  Negative regulation of nuclear division                                                          1.10 × 10^−4^    *CDC20, FGFR3, MAD2L1, PTTG1, PTTG3P, RGCC, UBE2C*
  Skin development                                                                                 1.82 × 10^−4^    *ALOX15B, FOXQ1, FZD6, SPRR1A, SPRR2A, SPRR2D, SPRR2E, SPRR3, TGM1, TMEM79, TXNIP*
  Peptide cross-linking                                                                            2.05 × 10^−4^    *SPRR1A, SPRR2A, SPRR2D, SPRR2E, SPRR3, TGM1*
  Serine family amino acid biosynthetic process                                                    3.55 × 10^−4^    *CBS, PHGDH, PSAT1, SHMT2*
  Regulation of collagen metabolic process                                                         5.84 × 10^−4^    *CTGF, F2R, FAP, IL6, RGCC*
  Regulation of multicellular organismal metabolic process                                         6.51 × 10^−4^    *CTGF, F2R, FAP, IL6, RGCC*
  Steroid biosynthesis                                                                             6.77 × 10^−4^    *CYP24A1, DHCR7, EBP, MSMO1*
  Chromosome separation                                                                            0.00192          *CDC20, MAD2L1, PTTG1, PTTG3P, TOP2A, UBE2C*
  Negative regulation of mitotic sister chromatid separation                                       0.00199          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Collagen metabolic process                                                                       0.00200          *COL12A1, CTGF, F2R, FAP, IL6, MMP12, RGCC*
  Negative regulation of mitotic sister chromatid segregation                                      0.00231          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Multicellular organismal macromolecule metabolic process                                         0.00248          *COL12A1, CTGF, F2R, FAP, IL6, MMP12, RGCC*
  Negative regulation of sister chromatid segregation                                              0.00267          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Negative regulation of chromosome segregation                                                    0.00267          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Regulation of nuclear division                                                                   0.00302          *AURKA, CDC20, FGFR3, MAD2L1, PTTG1, PTTG3P, RGCC, UBE2C*
  Multicellular organismal metabolic process                                                       0.00456          *COL12A1, CTGF, F2R, FAP, IL6, MMP12, RGCC*
  Regulation of collagen biosynthetic process                                                      0.00457          *CTGF, F2R, IL6, RGCC*
  Mitotic sister chromatid separation                                                              0.00664          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Regulation of mitotic sister chromatid segregation                                               0.00834          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Sister chromatid segregation                                                                     0.00851          *CDC20, CEP55, MAD2L1, PTTG1, PTTG3P, TOP2A, UBE2C*
  Glycine, serine and threonine metabolism                                                         0.00873          *CBS, PHGDH, PSAT1, SHMT2*
  Collagen biosynthetic process                                                                    0.00873          *CTGF, F2R, IL6, RGCC*
  Oocyte meiosis                                                                                   0.01153          *ADCY3, AURKA, CCNB2, CDC20, MAD2L1, PTTG1*
  Regulation of sister chromatid segregation                                                       0.01277          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Negative regulation of chromosome organization                                                   0.01396          *ARTN, CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  PERK-mediated unfolded protein response                                                          0.01404          *ASNS, ATF3, HSPA5*
  Regulation of stress fiber assembly                                                              0.01630          *CTGF, RGCC, RNASE1*
  FoxO signaling pathway                                                                           0.01634          *CCNB2, GABARAPL1, IL6, IRS2, PCK2, SGK1*
  Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process   0.01664          *AURKA, CDC20, MAD2L1, PTTG1, UBE2C*
  Alpha-amino acid biosynthetic process                                                            0.01664          *ASNS, CBS, PHGDH, PSAT1, SHMT2*
  Positive regulation of collagen biosynthetic process                                             0.02234          *CTGF, F2R, RGCC*
  Regulation of systemic arterial blood pressure by circulatory renin-angiotensin                  0.02412          *CPA4, F2R, MMP12*
  Positive regulation of multicellular organismal metabolic process                                0.02412          *CTGF, F2R, RGCC*
  Secondary alcohol biosynthetic process                                                           0.02578          *DHCR7, EBP, HMGCS1, MSMO1*
  Regulation of chromosome segregation                                                             0.02590          *CDC20, MAD2L1, PTTG1, PTTG3P, UBE2C*
  Negative regulation of proteasomal ubiquitin-dependent protein catabolic process                 0.03145          *CDC20, MAD2L1, UBE2C*

In red up-regulated and in green down-regulated genes in BE63/3 cells treated with 100 nM EVE compared to CTR.
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###### 

List of probe sets differentially expressed after treatment with 5 nM EVE.

  Probe ID   Fold Change   Regulation   Symbol      Entrez Gene ID   Definition
  ---------- ------------- ------------ ----------- ---------------- ------------------------------------------------------------------------------------
  2230035    7.508         up           KRT13       3860             keratin 13, transcript variant 2, mRNA.
  6510754    3.841         up           ALDH1A1     216              aldehyde dehydrogenase 1 family, member A1, mRNA.
  1070477    3.395         up           ALDH1A1     216              aldehyde dehydrogenase 1 family, member A1, mRNA.
  540546     2.749         up           KRT4        3851             keratin 4, mRNA.
  1990142    2.644         up           C20orf114   92747            chromosome 20 open reading frame 114, mRNA.
  5900368    2.385         up           MSMB        4477             microseminoprotein, beta-, transcript variant PSP94, mRNA.
  4610131    2.358         up           SPRR3       6707             small proline-rich protein 3, transcript variant 1, mRNA.
  3190110    2.194         up           MSMB        4477             microseminoprotein, beta-, transcript variant PSP94, mRNA.
  630315     2.151         up           DHRS9       10170            dehydrogenase/reductase (SDR family) member 9, transcript variant 1, mRNA.
  5420577    2.149         up           CLCA4       22802            chloride channel, calcium activated, family member 4, mRNA.
  5560369    2.107         up           ALDH3A1     218              aldehyde dehydrogenase 3 family, memberA1, mRNA.
  4150598    1.990         up           MSMB        4477             microseminoprotein, beta-, transcript variant PSP57, mRNA.
  1820414    1.897         up           ATP12A      479              ATPase, H^+^/K^+^ transporting, nongastric, alpha polypeptide, mRNA.
  3520709    1.888         up           ADH7        131              alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide, mRNA.
  7160468    1.807         up           DHRS9       10170            dehydrogenase/reductase (SDR family) member 9, transcript variant 1, mRNA.
  5310646    1.795         up           AKR1B10     57016            aldo-keto reductase family 1, member B10 (aldose reductase), mRNA.
  4250092    1.749         up           C10orf99    387695           chromosome 10 open reading frame 99, mRNA.
  110372     1.748         up           CSTA        1475             cystatin A (stefin A), mRNA.
  3710671    1.712         up           KRT15       3866             keratin 15, mRNA.
  1770603    1.705         up           TCN1        6947             transcobalamin I (vitamin B12 binding protein, R binder family), mRNA.
  6100537    1.655         up           FAM3D       131177           family with sequence similarity 3, member D, mRNA.
  4540400    1.623         up           CYP4B1      1580             cytochrome P450, family 4, subfamily B, polypeptide 1, transcript variant 2, mRNA.
  2900050    1.611         up           GSTA1       2938             glutathione S-transferase alpha 1, mRNA.
  1510170    1.565         up           NLRP2       55655            NLR family, pyrin domain containing 2, mRNA.
  5820400    1.526         up           CYP4B1      1580             cytochrome P450, family 4, subfamily B, polypeptide 1, mRNA.
  130561     1.525         up           GSTA4       2941             glutathione S-transferase A4, mRNA.
  3850246    1.513         up           HOPX        84525            HOP homeobox, transcript variant 3, mRNA.
  7200612    −1.522        down         LOC730417   730417           hypothetical protein LOC730417, mRNA.
  1510296    −1.556        down         ASNS        440              asparagine synthetase, transcript variant 1, mRNA.
  3290390    −1.563        down         LOC729841   729841           misc_RNA, miscRNA.
  7380193    −1.574        down         ARPC3       10094            actin related protein 2/3 complex, subunit 3, 21 kDa, mRNA.
  130717     −1.610        down         ARPC1B      10095            actin related protein 2/3 complex, subunit 1B, 41 kDa, mRNA.
  430446     −1.689        down         KRT81       3887             keratin 81, mRNA.

In red up-regulated and in green down-regulated genes in BE63/3 cells treated with 5 nM EVE compared to CTR.
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###### 

List of pathways differentially regulated after treatment with 5 nM EVE.

  PATHWAYS                                       Adj. *p* Value   Associated Genes Found
  ---------------------------------------------- ---------------- ---------------------------------
  Retinol metabolism                             8.58 × 10^−5^    ADH7, ALDH1A1, DHRS9
  Metabolism of xenobiotics by cytochrome P450   1.48 × 10^−5^    ADH7, ALDH3A1, GSTA1, GSTA4
  Drug metabolism                                1.37 × 10^−5^    ADH7, ALDH3A1, GSTA1, GSTA4
  Retinoid metabolic process                     1.41 × 10^−5^    ADH7, AKR1B10, ALDH1A1, DHRS9
  Chemical carcinogenesis                        1.96 × 10^−5^    ADH7, ALDH3A1, GSTA1, GSTA4
  Cellular aldehyde metabolic process            2.60 × 10^−5^    ADH7, AKR1B10, ALDH1A1, ALDH3A1
  Primary alcohol metabolic process              3.30 × 10^−6^    ADH7, AKR1B10, ALDH1A1, DHRS9
  Retinol metabolic process                      1.99 × 10^−5^    ADH7, ALDH1A1, DHRS9

In red up-regulated genes in BE63/3 cells treated with 5 nM EVE compared to CTR.
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###### 

List of microRNAs differentially regulated after treatment with 100 nM EVE.

  Systematic Name   Regulation   Fold Change
  ----------------- ------------ -------------
  hsa-miR-8485      up           5.372
  hsa-miR-937-5p    up           1.787
  hsa-miR-5194      up           1.694

ijms-19-01250-t006_Table 6

###### 

List of microRNAs differentially regulated after treatment with 5 nM EVE.

  Systematic Name   Regulation   Fold Change
  ----------------- ------------ -------------
  hsa-miR-8485      up           9.183
  hsa-miR-4730      up           2.900
  hsa-miR-5194      up           2.732
  hsa-miR-6716-3p   up           2.561
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###### 

miRNA/mRNA pairs matched on the basis of mRNA and miRNA profiling results.

  Cell Treatments   miRNA                                                         Fold Change   mRNA Target                                            Gene Name
  ----------------- ------------------------------------------------------------- ------------- ------------------------------------------------------ --------------------------------------------------------
  EVE 5 nM          miR-8485                                                      9.183         CYP4B1                                                 cytochrome P450, family 4, subfamily B, polypeptide 1
  miR-5194          2.732                                                         ARPC3         actin related protein 2/3 complex, subunit 3, 21 kDa   
  EVE 100 nM        miR-8485                                                      5.372         CYP24A1                                                cytochrome P450, family 24, subfamily A, polypeptide 1
  KAL1              Kallmann syndrome 1 sequence                                                                                                       
  UBL3              ubiquitin-like 3                                                                                                                   
  IRS2              insulin receptor substrate 2                                                                                                       
  CTGF              connective tissue growth factor                                                                                                    
  LBH               limb bud and heart development                                                                                                     
  FLRT2             fibronectin leucine rich transmembrane protein 2                                                                                   
  CDH6              cadherin 6, type 2, K-cadherin (fetal kidney)                                                                                      
  CYBRD1            cytochrome b reductase 1                                                                                                           
  LETMD1            LETM1 domain containing 1                                                                                                          
  FGFR3             fibroblast growth factor receptor 3                                                                                                
  CPA4              carboxypeptidase A4                                                                                                                
  AURKA             aurora kinase A                                                                                                                    
  CBS               cystathionine-beta-synthase                                                                                                        
  MAD2L1            MAD2 mitotic arrest deficient-like 1 (yeast)                                                                                       
  ADCY3             adenylate cyclase 3                                                                                                                
  TMEM79            transmembrane protein 79                                                                                                           
  IFIT1             interferon-induced protein with tetratricopeptide repeats 1                                                                        
  PTTG1             pituitary tumor-transforming 1                                                                                                     
  PCDH7             protocadherin 7                                                                                                                    
  miR-937-5p        1.787                                                         CDH6          cadherin 6, type 2, K-cadherin (fetal kidney)          
  KIAA0101          KIAA0101                                                                                                                           
  EMILIN2           elastin microfibril interfacer 2                                                                                                   
  miR-5194          1.694                                                         KLHL24        kelch-like family member 24                            
  FAP               fibroblast activation protein, alpha                                                                                               
  LBH               limb bud and heart development                                                                                                     
  PIM1              pim-1 oncogene                                                                                                                     
  FLRT2             fibronectin leucine rich transmembrane protein 2                                                                                   
  LETMD1            LETM1 domain containing 1                                                                                                          
  FGFR3             fibroblast growth factor receptor 3                                                                                                
  KIAA0101          KIAA0101                                                                                                                           
  RARRES3           retinoic acid receptor responder (tazarotene induced) 3                                                                            
  ARTN              artemin                                                                                                                            
  IGFBP6            insulin-like growth factor binding protein 6                                                                                       
  LCP1              lymphocyte cytosolic protein 1 (L-plastin)                                                                                         
  MALL              small integral membrane protein 5                                                                                                  
  SCD               LSM14B, SCD6 homolog B (*S. cerevisiae*)                                                                                           
  IFIT1             interferon-induced protein with tetratricopeptide repeats 1                                                                        

In red up-regulated and in green down-regulated genes in BE63/3 cells treated with EVE (5 or 100 nM) compared to CTR.
